Who are Trishula Therapeutics, Inc.'s investors?

Trishula Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Astellas Venture Management LLC, Lightstone Ventures.

Trishula Therapeutics, Inc.

8 employees on LinkedIn · 4 known investors

Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.

Biotech Healthtech

Founders & leadership

Anil SinghalPresident and CEO

Siddhartha MitraChief Medical Officer

Investors · 4

Canaan Partners✓ verifiedStamford · $500K – $20M

MPM BioImpact✓ verifiedBoston · $1M – $15M

Astellas Venture Management LLCSouth San Francisco · $200K – $5M

Lightstone VenturesPortola Valley

Competitors · 2

by search overlap

Solu6 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Tizona Therapeutics, Inc.3 shared keywordsTizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.

Companies competing with Trishula Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancerprnewswire.com · Apr 2022

Frequently asked questions

What does Trishula Therapeutics, Inc. do?: Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.
Who are Trishula Therapeutics, Inc.'s investors?: Trishula Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Astellas Venture Management LLC, Lightstone Ventures.